Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Fairmount Funds Management LLC
Form 13F · Q2 2026

Fairmount Funds Management LLC

CIK 1802528Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$1.5B
Reported book value
12
Positions
12
Quarters on record
Top 50
Positions

Fairmount Funds Management LLC — holdings

Top 12 positions of 12, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1ORKA Oruka Therapeutics Inc3.7M+0.0%$353M23.3%
2DNTH Dianthus Therapeutics Inc2.5M+0.0%$247M16.3%
3DMRA Damora Therapeutics Inc8.7M+0.0%$227M15.0%
4COGT Cogent Biosciences Inc5.5M+0.0%$213M14.1%
5JBIO Jade Biosciences Inc4.6M+0.0%$101M6.7%
6ELVN Enliven Therapeutics Inc1.9M+0.0%$94M6.2%
7VRDN Viridian Therapeutics Inc5.1M+30.1%$94M6.2%
8ZBIO Zenas Biopharma Inc2.4M+0.0%$60M4.0%
9CBIO Crescent Biopharma Inc.2.7M+0.0%$49M3.3%
10APOGEE THERAPEUTICS INC Apogee Therapeutics Inc298,647+0.0%$40M2.6%
11FTH Faeth Therapeutics Inc722,020—$18M1.2%
12IKT Inhibikase Therapeutics Inc8.6M+0.0%$18M1.2%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.